AWKN-001
Phase 3- Indications
- Alcohol Use Disorder
Company intelligence / Profile preview
Awakn has demonstrated clinical efficacy with its ketamine-assisted therapy program for Severe Alcohol Use Disorder. The company’s lead program was licensed from the University of Exeter following positive Phase II results. A pivotal Phase III trial was planned to start in H2 2023. Preclinical work continues on novel compounds targeting trauma-related mental health conditions such as PTSD.
2 more assets in the full pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Awakn Life Sciences.